title: The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.
abstract: To date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streamline 30 years of research and ask a set of important questions: in Type 1 diabetes which glycation products correlate best with 1) past mean glycemia 2) reversibility with improved glycemic control, 2) cross-sectional severity of retinopathy, nephropathy and neuropathy and 3) the future long-term risk of progression of micro- and subclinical macrovascular disease. The trio of glycemia related glycation markers furosine (FUR)/fructose-lysine (FL), glucosepane and methylglyoxal hydroimidazolone (MG-H1) emerges as extraordinarily strong predictors of existing and future microvascular disease progression risk despite adjustment for both past and prospective A1c levels. X(2) values are up to 25.1, p values generally less than 0.0001, and significance remains after adjustment for various factors such as A1c, former treatment group, log albumin excretion rate, abnormal autonomic nerve function and LDL levels at baseline. In contrast, subclinical cardiovascular progression is more weakly correlated with AGEs/glycemia with X(2) values < 5.0 and p values generally < 0.05 after all adjustments. Except for future carotid intima-media thickness, which correlates with total AGE burden (MG-H1, pentosidine, fluorophore LW-1 and decreased collagen solubility), adjusted FUR and Collagen Fluorescence (CLF) are the strongest markers for future coronary artery calcium deposition, while cardiac hypertrophy is associated with LW-1 and CLF adjusted for A1c. We conclude that a robust clinical skin biopsy AGE risk panel for microvascular disease should include at least FUR/FL, glucosepane and MG-H1, while a macrovascular disease risk panel should include at least FL/FUR, MG-H1, LW-1 and CLF.
authors.affiliation: Department of Pathology, Case Western Reserve University, Cleveland, OH, 44106, USA. vmm3@cwru.edu.|Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA. vmm3@cwru.edu.
authors.forename: Vincent M
authors.initials: VM
authors.lastname: Monnier
authors.affiliation: Department of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.
authors.forename: Saul
authors.initials: S
authors.lastname: Genuth
authors.affiliation: Department of Pathology, Case Western Reserve University, Cleveland, OH, 44106, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Sell
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D012867:Skin / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced
keywords: Coronary artery calcium; Glycation; Intima media thickness; Left ventricular mass; Methylglyoxal; Nephropathy; Neuropathy; Oxidation; Retinopathy